questionsmedicales.fr
Composés polycycliques
Hydrocarbures aromatiques polycycliques
Benzocycloheptènes
Benzocycloheptènes : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Spectroscopie
Chromatographie
Tests de toxicité
Efficacité
Analyse sanguine
Échantillons biologiques
Marqueurs biologiques
Exposition
Imagerie moléculaire
Distribution tissulaire
Symptômes
5
Effets secondaires
Réactions allergiques
Symptômes neurologiques
Troubles de la coordination
Éruptions cutanées
Réaction allergique
Système respiratoire
Irritations
Prévention
5
Équipements de protection
Protocoles de sécurité
Milieu industriel
Exposition
Réglementations
Usage industriel
Évaluation des risques
Environnements de travail
Traitements
5
Intoxication
Soins symptomatiques
Antidotes
Composés chimiques
Antihistaminiques
Réactions allergiques
Hospitalisation
Symptômes graves
Suivi médical
Effets à long terme
Complications
5
Complications
Lésions organiques
Cancers
Potentiel cancérigène
Effets sur la reproduction
Études animales
Allergies
Sensibilisations
Système immunitaire
Infections
Facteurs de risque
5
Travailleurs
Industrie chimique
Prédispositions génétiques
Sensibilité aux toxines
Antécédents médicaux
Allergies
Environnement de travail
Ventilation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Benzocycloheptènes : Questions médicales les plus fréquentes",
"headline": "Benzocycloheptènes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Benzocycloheptènes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-11",
"dateModified": "2025-03-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Benzocycloheptènes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hydrocarbures aromatiques polycycliques",
"url": "https://questionsmedicales.fr/mesh/D011084",
"about": {
"@type": "MedicalCondition",
"name": "Hydrocarbures aromatiques polycycliques",
"code": {
"@type": "MedicalCode",
"code": "D011084",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Dibenzocycloheptènes",
"alternateName": "Dibenzocycloheptenes",
"url": "https://questionsmedicales.fr/mesh/D003986",
"about": {
"@type": "MedicalCondition",
"name": "Dibenzocycloheptènes",
"code": {
"@type": "MedicalCode",
"code": "D003986",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Amitriptyline",
"alternateName": "Amitriptyline",
"url": "https://questionsmedicales.fr/mesh/D000639",
"about": {
"@type": "MedicalCondition",
"name": "Amitriptyline",
"code": {
"@type": "MedicalCode",
"code": "D000639",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Butaclamol",
"alternateName": "Butaclamol",
"url": "https://questionsmedicales.fr/mesh/D002069",
"about": {
"@type": "MedicalCondition",
"name": "Butaclamol",
"code": {
"@type": "MedicalCode",
"code": "D002069",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.230"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cyproheptadine",
"alternateName": "Cyproheptadine",
"url": "https://questionsmedicales.fr/mesh/D003533",
"about": {
"@type": "MedicalCondition",
"name": "Cyproheptadine",
"code": {
"@type": "MedicalCode",
"code": "D003533",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Loratadine",
"alternateName": "Loratadine",
"url": "https://questionsmedicales.fr/mesh/D017336",
"about": {
"@type": "MedicalCondition",
"name": "Loratadine",
"code": {
"@type": "MedicalCode",
"code": "D017336",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Loratadine",
"alternateName": "Loratadine",
"url": "https://questionsmedicales.fr/mesh/D017336",
"about": {
"@type": "MedicalCondition",
"name": "Loratadine",
"code": {
"@type": "MedicalCode",
"code": "D017336",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Maléate de dizocilpine",
"alternateName": "Dizocilpine Maleate",
"url": "https://questionsmedicales.fr/mesh/D016291",
"about": {
"@type": "MedicalCondition",
"name": "Maléate de dizocilpine",
"code": {
"@type": "MedicalCode",
"code": "D016291",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.380"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nortriptyline",
"alternateName": "Nortriptyline",
"url": "https://questionsmedicales.fr/mesh/D009661",
"about": {
"@type": "MedicalCondition",
"name": "Nortriptyline",
"code": {
"@type": "MedicalCode",
"code": "D009661",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.535"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protriptyline",
"alternateName": "Protriptyline",
"url": "https://questionsmedicales.fr/mesh/D011530",
"about": {
"@type": "MedicalCondition",
"name": "Protriptyline",
"code": {
"@type": "MedicalCode",
"code": "D011530",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.650"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Benzocycloheptènes",
"alternateName": "Benzocycloheptenes",
"code": {
"@type": "MedicalCode",
"code": "D001567",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jiatian Li",
"url": "https://questionsmedicales.fr/author/Jiatian%20Li",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Xiangwen Tan",
"url": "https://questionsmedicales.fr/author/Xiangwen%20Tan",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Huanfeng Jiang",
"url": "https://questionsmedicales.fr/author/Huanfeng%20Jiang",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Wanqing Wu",
"url": "https://questionsmedicales.fr/author/Wanqing%20Wu",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Implementation of Canada's youth justice minimum age of 12: implications for children in Canada and globally.",
"datePublished": "2022-07-26",
"url": "https://questionsmedicales.fr/article/35882947",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1057/s41271-022-00358-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Palliative care stakeholders in Canada.",
"datePublished": "2022-06-06",
"url": "https://questionsmedicales.fr/article/35668462",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12961-022-00855-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Access to Cancer Drugs in Canada.",
"datePublished": "2022-10-12",
"url": "https://questionsmedicales.fr/article/36290875",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/curroncol29100598"
}
},
{
"@type": "ScholarlyArticle",
"name": "The state of tuberculosis surveillance in Canada.",
"datePublished": "2023-04-04",
"url": "https://questionsmedicales.fr/article/37014575",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.17269/s41997-023-00767-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Etiology of problem gambling in Canada.",
"datePublished": "2022-07-04",
"url": "https://questionsmedicales.fr/article/35787101",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1037/adb0000843"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011083"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures aromatiques polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011084"
},
{
"@type": "ListItem",
"position": 4,
"name": "Benzocycloheptènes",
"item": "https://questionsmedicales.fr/mesh/D001567"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Benzocycloheptènes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Benzocycloheptènes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Benzocycloheptènes",
"description": "Comment identifier les benzocycloheptènes ?\nQuels tests sont utilisés pour les benzocycloheptènes ?\nLes benzocycloheptènes sont-ils détectables dans le sang ?\nY a-t-il des marqueurs spécifiques pour ces composés ?\nPeut-on utiliser l'imagerie pour les benzocycloheptènes ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Canada#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Benzocycloheptènes",
"description": "Quels sont les effets secondaires des benzocycloheptènes ?\nLes benzocycloheptènes causent-ils des douleurs ?\nY a-t-il des symptômes neurologiques associés ?\nPeut-on observer des symptômes cutanés ?\nLes benzocycloheptènes affectent-ils le système respiratoire ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Canada#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Benzocycloheptènes",
"description": "Comment prévenir l'exposition aux benzocycloheptènes ?\nY a-t-il des formations pour manipuler ces composés ?\nQuels sont les risques en milieu industriel ?\nDes réglementations existent-elles pour leur usage ?\nComment évaluer les risques d'exposition ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Canada#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Benzocycloheptènes",
"description": "Comment traiter une intoxication aux benzocycloheptènes ?\nY a-t-il des antidotes pour ces composés ?\nQuels médicaments peuvent aider en cas d'allergie ?\nLes benzocycloheptènes nécessitent-ils une hospitalisation ?\nComment gérer les effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Canada#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Benzocycloheptènes",
"description": "Quelles complications peuvent survenir avec ces composés ?\nLes benzocycloheptènes peuvent-ils causer des cancers ?\nY a-t-il des effets sur la reproduction ?\nPeut-on développer des allergies à long terme ?\nLes benzocycloheptènes affectent-ils le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Canada#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Benzocycloheptènes",
"description": "Qui est le plus à risque d'exposition ?\nL'âge influence-t-il la sensibilité ?\nY a-t-il des prédispositions génétiques ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'environnement de travail influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Canada#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les benzocycloheptènes ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des techniques de spectroscopie et de chromatographie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les benzocycloheptènes ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de toxicité et d'efficacité sont réalisés en laboratoire."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes sont-ils détectables dans le sang ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être détectés par des analyses spécifiques dans des échantillons biologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour ces composés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs biologiques peuvent indiquer l'exposition à ces composés."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour les benzocycloheptènes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie moléculaire peut aider à visualiser leur distribution dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des benzocycloheptènes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent provoquer des nausées, des vertiges ou des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes causent-ils des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs peuvent survenir en cas de toxicité ou d'allergie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des maux de tête ou des troubles de la coordination peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent survenir en cas de réaction allergique."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes affectent-ils le système respiratoire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition excessive peut entraîner des irritations respiratoires."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition aux benzocycloheptènes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection et suivre les protocoles de sécurité en laboratoire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des formations pour manipuler ces composés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des formations spécifiques sont souvent requises pour les chercheurs."
}
},
{
"@type": "Question",
"name": "Quels sont les risques en milieu industriel ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs peuvent être exposés à des niveaux élevés sans protection adéquate."
}
},
{
"@type": "Question",
"name": "Des réglementations existent-elles pour leur usage ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des réglementations strictes encadrent leur utilisation en laboratoire et en industrie."
}
},
{
"@type": "Question",
"name": "Comment évaluer les risques d'exposition ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des évaluations de risque doivent être effectuées régulièrement dans les environnements de travail."
}
},
{
"@type": "Question",
"name": "Comment traiter une intoxication aux benzocycloheptènes ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'élimination de l'exposition et des soins symptomatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des antidotes pour ces composés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas d'antidote spécifique pour les benzocycloheptènes."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent aider en cas d'allergie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antihistaminiques peuvent être utilisés pour traiter les réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes nécessitent-ils une hospitalisation ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une hospitalisation peut être nécessaire en cas de symptômes graves."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier est recommandé pour surveiller les effets à long terme."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces composés ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des lésions organiques peuvent survenir en cas d'exposition prolongée."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes peuvent-ils causer des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un potentiel cancérigène, mais des recherches supplémentaires sont nécessaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets sur la reproduction ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets néfastes sur la reproduction ont été observés dans certaines études animales."
}
},
{
"@type": "Question",
"name": "Peut-on développer des allergies à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des sensibilisations peuvent se développer avec une exposition répétée."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes affectent-ils le système immunitaire ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut altérer la fonction immunitaire, augmentant les infections."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque d'exposition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs en laboratoire et en industrie chimique sont les plus exposés."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la sensibilité ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes et les personnes âgées peuvent être plus sensibles aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines prédispositions génétiques peuvent augmenter la sensibilité aux toxines."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents d'allergies ou de maladies respiratoires augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'environnement de travail influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un environnement de travail mal ventilé augmente le risque d'exposition."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 08/03/2025
Contenu vérifié selon les dernières recommandations médicales
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China.
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China.
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China.
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China.
Publications dans "Benzocycloheptènes" :
Youth justice minimum age thresholds vary widely and are garnering increased global attention. In 1984, legislation in Canada excluded all children under age 12 from its youth justice system, yet few ...
Improving access to palliative care for Canadians requires a focused collective effort towards palliative and end-of-life care advocacy and policy. However, evolution of modern palliative care in Cana...
A systematic grey literature search was conducted examining policy documents (i.e. policy reports, legislative bills, judicial court cases) in the field of palliative care, end-of-life care and medica...
Over 800 organizations contributed to 115 documents (41 policy reports, 11 legislative, 63 judicial). Discussions regarding national palliative care policy over the last two decades peaked in 2016. St...
Stakeholders from various societal sectors have contributed to national palliative care conversions over the past two decades; however, not all the stakeholder organizations engaged to the same extent...
Lung cancer, because of the multiple subtypes now identifiable and because of the myriad of new and effective therapies, provides fertile ground to highlight issues related to oncology drug access in ...
Tuberculosis incidence in Canada has remained essentially unchanged over the past decade. A strategic plan to reduce the burden of disease, underpinned by high-quality surveillance data, is sorely nee...
To conduct a large-scale national cohort study to identify the current etiological risk factors for problem gambling in Canada....
A cohort of 10,119 Canadian gamblers completed a comprehensive self-administered online questionnaire in 2018 and were reassessed in 2019. At baseline, the sample contained 1,388 at-risk gamblers, 1,3...
The strongest multivariate predictors of current and future problem gambling were "gambling-related" variables (i.e., current and past problem gambling, intensive gambling involvement, playing electro...
The predictors of problematic gambling in the present study are very similar to the predictors identified in prior international longitudinal and cross-sectional research. This implies core cross-cult...
Hepatitis B surface antigen (HBsAg) loss is associated with improved clinical outcomes for individuals with chronic hepatitis B (CHB); however, the effects of varying HBsAg levels on clinical outcomes...
In this cross-sectional, multicentre, retrospective study, the data on adult subjects enrolled in the Canadian HBV Network with CHB seen from 1 January 2012 to 30 January 2021 with the treatment and v...
This study included 844 CHB patients, with a median age of 49.6 years (IQR 40.1-60.5), and 37% were female. In total, 751 patients (78.6%) had known ethnicity data, and 76.7% self-reported as Asian, 1...
In this retrospective, ethnically diverse cohort study, CHB patients who received antiviral therapy and/or had HBsAg loss were less likely to develop cirrhosis and HCC, confirming the results of the s...
Osteoporosis Canada 2023 clinical practice guidelines increase the number of individuals recommended or suggested for anti-osteoporosis pharmacotherapy by refining treatment guidance for those who fel...
In 2023, Osteoporosis Canada updated its 2010 clinical practice guidelines based upon consideration of fracture history, 10-year major osteoporotic fracture (MOF) risk, and BMD T-score in conjunction ...
The study population consisted of 79,654 individuals age ≥ 50 years undergoing baseline DXA testing from January 1996 to March 2018. Each individual was assigned to mutually exclusive categories based...
Treatment reclassification under the 2023 guidelines only affected 33.8% of individuals in the 2010 moderate-risk group, with 13.0% assigned to no treatment, 14.4% to suggest treatment, and 6.4% to re...
Osteoporosis Canada 2023 clinical practice guidelines affect individuals within the 2010 moderate-risk category, increasing the number for whom anti-osteoporosis pharmacotherapy is recommended or sugg...
Cost of illness studies are important tools to summarise the burden of disease for individuals, the healthcare system and society. The lack of standardised methods for reporting costs for cystic fibro...
The total cost of CF in Canada was calculated by triangulating information from three sources (Canadian CF Registry, customised Burden of Disease survey and publicly available information). A prevalen...
The total socioeconomic burden of CF in Canada in 2021 across the four perspectives was $C414 million. Direct costs accounted for two-thirds of the total costs, with medications comprising half of all...
This comprehensive cost of illness study for CF represents a community-oriented approach describing the socioeconomic burden of living with CF and serves as a benchmark for future studies....
Contemporary estimates of diabetes mellitus (DM) rates in pregnancy are lacking in Canada. Accordingly, this study examined trends in the rates of type 1 (T1DM), type 2 (T2DM) and gestational (GDM) DM...
This study used repeated cross-sectional data from the Canadian Institute of Health Information (CIHI) hospitalization discharge abstract database (DAD). Maternal delivery records were linked to their...
Over the 15-year study period, comprising 4,320,778 hospital deliveries in Canada, there was a statistically significant increase in the prevalence of GDM and T1DM and T2DM. Compared to pregnancies wi...
Among 4.3 million pregnancies in Canada, there has been a rise in the prevalence of DM. T2DM and GDM are expected to increase further as more overweight women conceive in Canada....
This paper aims to capture the effect of environmentally related taxes on environmental quality in Canada while controlling economic growth, financial development, and energy consumption over the peri...